Literature DB >> 11904403

Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.

Gunter Kraus1, Rebeca Geffin, Gina Spruill, Andrea K Young, Rachel Seivright, Diana Cardona, Jennifer Burzawa, H James Hnatyszyn.   

Abstract

RNase P complexes have been proposed as a novel RNA-based gene interference strategy to inhibit gene expression in human malignancies and infectious diseases. This approach is based on the sequence-specific design of an external guide sequence (EGS) RNA molecule that can specifically hybridize to almost any complementary target mRNA and facilitate its cleavage by the RNase P enzyme component. We designed a truncated RNase P-associated EGS molecule to specifically recognize the U5 region of HIV-1 mRNA and mediate cleavage of hybridized mRNA by the RNase P enzyme. Genes encoding for this U5-EGS (560) molecule, as well as a U5 EGS (560D) antisense control, were cloned into retroviral plasmids and transferred into a CD4(+) T cell line. Transfected cells were exposed to increasing concentrations of HIV-1 clinical isolates from clades A, B, C, and F. Heterogeneous cultures of CD4(+) T cells expressing the U5 EGS (560) molecule were observed to maintain CD4 levels, were devoid of cytopathology, and did not produce HIV p24 gag antigen through 30 days after exposure to all HIV-1 clades at a multiplicity of infection of 0.01. Identical cells expressing the U5 EGS (560D) antisense control molecule underwent a loss of CD4 expression, produced elevated levels of HIV-1, and formed large syncytia similar to untreated cells. When the viral inoculum was increased at the time of exposure (multiplicity of infection = 0.05), the inhibitory effect of the U5 EGS (560) molecule was overwhelmed, but viral-mediated cytopathology and particle production were delayed compared with control cell populations. Viral replication and cytopathology associated with infection of multiple HIV-1 clades can be effectively inhibited in CD4(+) cells expressing the RNase P-associated U5 EGS (560) molecule.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11904403      PMCID: PMC122536          DOI: 10.1073/pnas.052651199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

Review 1.  RNase P: from biological function to biotechnological applications.

Authors:  C Cobaleda; I Sánchez-García
Journal:  Trends Biotechnol       Date:  2001-10       Impact factor: 19.536

2.  Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

Authors:  R Kikukawa; Y Koyanagi; S Harada; N Kobayashi; M Hatanaka; N Yamamoto
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

3.  Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis.

Authors:  H Hnatyszyn; G Spruill; A Young; R Seivright; G Kraus
Journal:  Gene Ther       Date:  2001-12       Impact factor: 5.250

4.  The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

Authors:  S Jensen-Fangel; O Kirk; A Blaxhult; J Gerstoft; C Pedersen; F T Black; J D Lundgren; N Obel
Journal:  HIV Clin Trials       Date:  2001 Mar-Apr

5.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

6.  HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy.

Authors:  J Servais; D Nkoghe; J C Schmit; V Arendt; I Robert; T Staub; M Moutschen; F Schneider; R Hemmer
Journal:  J Acquir Immune Defic Syndr       Date:  2001-11-01       Impact factor: 3.731

7.  Recognition of engineered tRNAs with an extended 3' end by Exportin-t (Xpo-t) and transport of tRNA-attached ribozymes to the cytoplasm in somatic cells.

Authors:  T Kuwabara; M Warashina; M Sano; H Tang; F Wong-Staal; E Munekata; K Taira
Journal:  Biomacromolecules       Date:  2001       Impact factor: 6.988

8.  Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.

Authors:  J E Fitzgibbon; S Gaur; S M Walsman; M Janahi; P Whitley-Williams; J F John
Journal:  AIDS Res Hum Retroviruses       Date:  2001-09-20       Impact factor: 2.205

9.  Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1.

Authors:  O Yamada; M Yu; J K Yee; G Kraus; D Looney; F Wong-Staal
Journal:  Gene Ther       Date:  1994-01       Impact factor: 5.250

10.  Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes.

Authors:  M C Leavitt; M Yu; O Yamada; G Kraus; D Looney; E Poeschla; F Wong-Staal
Journal:  Hum Gene Ther       Date:  1994-09       Impact factor: 5.695

View more
  8 in total

Review 1.  Inhibition of gene expression in human cells using RNase P-derived ribozymes and external guide sequences.

Authors:  Kihoon Kim; Fenyong Liu
Journal:  Biochim Biophys Acta       Date:  2007-09-29

2.  Engineered external guide sequences effectively block viral gene expression and replication in cultured cells.

Authors:  Xiaohong Jiang; Yong Bai; Paul Rider; Kihoon Kim; Chen-Yu Zhang; Sangwei Lu; Fenyong Liu
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

3.  Directing RNase P-mediated cleavage of target mRNAs by engineered external guide sequences in cultured cells.

Authors:  Xiaohong Jiang; Naresh Sunkara; Sangwei Lu; Fenyong Liu
Journal:  Methods Mol Biol       Date:  2014

4.  Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P.

Authors:  Jiaming Zhu; Phong Trang; Kihoon Kim; Tianhong Zhou; Hongyu Deng; Fenyong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

5.  Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL.

Authors:  Yuichiro Habu; Naoko Miyano-Kurosaki; Michiko Kitano; Yumihiko Endo; Masakazu Yukita; Shigeru Ohira; Hiroaki Takaku; Masayuki Nashimoto; Hiroshi Takaku
Journal:  Nucleic Acids Res       Date:  2005-01-12       Impact factor: 16.971

6.  Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).

Authors:  David H Dreyfus; S Mark Tompkins; Ramsay Fuleihan; Lucy Y Ghoda
Journal:  Biologics       Date:  2007-12

7.  RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1.

Authors:  Wenbo Zeng; Gia-Phong Vu; Yong Bai; Yuan-Chuan Chen; Phong Trang; Sangwei Lu; Gengfu Xiao; Fenyong Liu
Journal:  Biomed Res Int       Date:  2012-12-27       Impact factor: 3.411

8.  Effective inhibition of human immunodeficiency virus 1 replication by engineered RNase P ribozyme.

Authors:  Wenbo Zeng; Yuan-Chuan Chen; Yong Bai; Phong Trang; Gia-Phong Vu; Sangwei Lu; Jianguo Wu; Fenyong Liu
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.